Free Trial

Astra Zeneca: Bullish Note From Company

HEALTHCARE

Astra Zeneca {AZN: A2/A): Company Update


Astra Zeneca released a bullish note today in which they anticipate:

  • Revenue of $80b annually by 2030 (up from $45b 2023)
  • 20 new drugs delivered – many with $5bn Peak Year revenues.
  • Growth coming from Oncology, BioPharma and Rare Disease portfolio.

Investor day link: {www.astrazeneca.com/investor-relations/astrazeneca-investor-day.html}

51 words

To read the full story

Close

Why MNI

MNI is the leading provider

of intelligence and analysis on the Global Fixed Income, Foreign Exchange and Energy markets. We use an innovative combination of real-time analysis, deep fundamental research and journalism to provide unique and actionable insights for traders and investors. Our "All signal, no noise" approach drives an intelligence service that is succinct and timely, which is highly regarded by our time constrained client base.

Our Head Office is in London with offices in Chicago, Washington and Beijing, as well as an on the ground presence in other major financial centres across the world.

Astra Zeneca {AZN: A2/A): Company Update


Astra Zeneca released a bullish note today in which they anticipate:

  • Revenue of $80b annually by 2030 (up from $45b 2023)
  • 20 new drugs delivered – many with $5bn Peak Year revenues.
  • Growth coming from Oncology, BioPharma and Rare Disease portfolio.

Investor day link: {www.astrazeneca.com/investor-relations/astrazeneca-investor-day.html}